{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Tumours&page=69",
    "query": {
      "condition": "Neuroendocrine Tumours",
      "page": 69
    },
    "page_size": 10
  },
  "pagination": {
    "page": 69,
    "page_size": 10,
    "total_count": 2739,
    "total_pages": 274,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Tumours&page=70&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Tumours&page=68&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-25T13:49:24.489Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02900248",
      "title": "CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neoplasms",
        "Lung Neoplasms",
        "Colon Neoplasms",
        "Breast Neoplasms",
        "Pancreatic Neoplasms",
        "Prostate Neoplasms",
        "Kidney Neoplasms",
        "Liver Neoplasms",
        "Rectal Neoplasms",
        "Hematologic Neoplasms",
        "Multiple Myeloma",
        "Myelodysplastic Syndromes",
        "Ovarian Neoplasms",
        "Bladder Neoplasms",
        "Testicular Neoplasms",
        "Endometrial Neoplasms",
        "Brain Neoplasms",
        "Biliary Tract Neoplasms",
        "Head and Neck Neoplasms",
        "Uterine Cervical Neoplasms",
        "Skin Neoplasms",
        "Melanoma",
        "Gastric Neoplasms",
        "Anal Neoplasms",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "Provider determined",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "CureOne",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2017-10-02",
      "completion_date": "2019-03-29",
      "has_results": false,
      "last_update_posted_date": "2019-04-02",
      "last_synced_at": "2026-10-25T13:49:24.489Z",
      "location_count": 1,
      "location_summary": "Idaho Falls, Idaho",
      "locations": [
        {
          "city": "Idaho Falls",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02900248"
    },
    {
      "nct_id": "NCT02250885",
      "title": "KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Neuroendocrine"
      ],
      "interventions": [
        {
          "name": "Selinexor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gabrail Cancer Center Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2014-08",
      "completion_date": "2016-08",
      "has_results": false,
      "last_update_posted_date": "2019-09-17",
      "last_synced_at": "2026-10-25T13:49:24.489Z",
      "location_count": 1,
      "location_summary": "Canton, Ohio",
      "locations": [
        {
          "city": "Canton",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02250885"
    },
    {
      "nct_id": "NCT05061940",
      "title": "This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Head and Neck Cancer",
        "Melanoma",
        "HPV-Related Malignancy",
        "HPV-Related Carcinoma",
        "HPV-Related Cervical Carcinoma",
        "HPV Positive Oropharyngeal Squamous Cell Carcinoma",
        "Lung Cancer, Nonsmall Cell",
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "Tumor Profiling",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Repertoire Immune Medicines",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2021-05-05",
      "completion_date": "2022-10-11",
      "has_results": false,
      "last_update_posted_date": "2022-12-06",
      "last_synced_at": "2026-10-25T13:49:24.489Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Ann Arbor, Michigan • Nashville, Tennessee",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05061940"
    },
    {
      "nct_id": "NCT01721746",
      "title": "A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Unresectable or Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "BMS-936558",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Dacarbazine",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 405,
      "start_date": "2012-12-21",
      "completion_date": "2020-12-29",
      "has_results": true,
      "last_update_posted_date": "2022-04-19",
      "last_synced_at": "2026-10-25T13:49:24.489Z",
      "location_count": 32,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 23 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francciso",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01721746"
    },
    {
      "nct_id": "NCT01068470",
      "title": "Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Melanoma",
        "Kidney Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Loma Linda University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2009-11",
      "completion_date": "2012-03",
      "has_results": false,
      "last_update_posted_date": "2014-05-29",
      "last_synced_at": "2026-10-25T13:49:24.489Z",
      "location_count": 1,
      "location_summary": "Beaumont, California",
      "locations": [
        {
          "city": "Beaumont",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01068470"
    },
    {
      "nct_id": "NCT02293954",
      "title": "Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer",
        "Colon Cancer",
        "Extrahepatic Bile Duct Cancer",
        "Gallbladder Cancer",
        "Gastrointestinal Cancer",
        "Liver and Intrahepatic Biliary Tract Cancer",
        "Lung Cancer",
        "Metastatic Cancer",
        "Pancreatic Cancer",
        "Rectal Cancer",
        "Thyroid Gland Medullary Carcinoma",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "radionuclide imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "positron emission tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "Cu 64 anti-CEA monoclonal antibody M5A IV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2015-11-11",
      "completion_date": "2027-07-14",
      "has_results": true,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-10-25T13:49:24.489Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02293954"
    },
    {
      "nct_id": "NCT04356729",
      "title": "A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Stage IV Melanoma",
        "Unresectable Stage III Cutaneous Melanoma",
        "Unresectable Stage IV Cutaneous Melanoma"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "F. Stephen Hodi, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2020-08-06",
      "completion_date": "2028-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-05",
      "last_synced_at": "2026-10-25T13:49:24.489Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04356729"
    },
    {
      "nct_id": "NCT00254579",
      "title": "Study of CP-675,206 in Refractory Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Refractory Melanoma"
      ],
      "interventions": [
        {
          "name": "CP-675,206",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 251,
      "start_date": "2005-12",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2012-06-07",
      "last_synced_at": "2026-10-25T13:49:24.489Z",
      "location_count": 36,
      "location_summary": "Scottsdale, Arizona • Bentonville, Arkansas • Fayetteville, Arkansas + 26 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Bentonville",
          "state": "Arkansas"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00254579"
    },
    {
      "nct_id": "NCT07704918",
      "title": "Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Statins (atorvastatin, rosuvastatin, simvastatin, or pravastatin), +/- ezetimibe, +/- PCSK9 inhibitor (alirocumab, evolocumab, inclisiran)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2026-10-19",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-22",
      "last_synced_at": "2026-10-25T13:49:24.489Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07704918"
    },
    {
      "nct_id": "NCT04609566",
      "title": "Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Non-small Cell Lung Cancer",
        "Squamous Cell Carcinoma of the Head and Neck"
      ],
      "interventions": [
        {
          "name": "brentuximab vedotin",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen, a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 161,
      "start_date": "2021-01-26",
      "completion_date": "2026-02-03",
      "has_results": false,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-10-25T13:49:24.489Z",
      "location_count": 90,
      "location_summary": "Tucson, Arizona • Fayetteville, Arkansas • Rogers, Arkansas + 57 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04609566"
    }
  ]
}